Potential new targets for antithrombotic therapy

Current Pharmaceutical Design

Volumn 9, Issue 28, 2003, Pages 2367-2374

  Gruber, A ^a   Hanson, S R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ANAGRELIDE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIOLIPIN; CLOPIDOGREL; FIBRINOLYTIC AGENT; GLYCOSPHINGOLIPID; HEPARIN; HYDROXYUREA; LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; OXIDIZED LOW DENSITY LIPOPROTEIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; RECOMBINANT PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STREPTOKINASE; TENECTEPLASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UNINDEXED DRUG; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; HEMOSTASIS; HUMAN; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; THROMBOCYTE COUNT; THROMBOGENESIS; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PROTEIN C; SELECTINS; THROMBIN; THROMBOSIS;

EID: 0141954076     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033453938     Document Type: Review

References (119)

1. Buller HR. Treatment of symptomatic venous thromboembolism: improving outcomes. Semin Thromb Hemost 2002; 28: 4-48.
2. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002; 23: 25-32.
3. Willerson JT, Zoldhelyi P. Future directions in thrombolysis. Clin Cardiol 1999; 22: 44-53.
4. Giangrande PL. Fondaparinux (Arixtra): a new anticoagulant. Int J Clin Pract 2002; 56: 615-7.
5. Turpie AG. State of the art - a journey through the world of antithrombotic therapy. Semin Thromb Hemost 2002; 28: 3-11.
6. Kandzari DE, Tcheng JE and Zidar JP. Coronary artery stents: evaluating new designs for contemporary percutaneous intervention. Catheter Cardiovasc Interv 2002; 56: 562-76.
7. Leadley, RJ Jr, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J Pharmacol Toxicol Methods 2000; 43: 101-16.
8. Reyers I, Mussoni L, Donati MB, de Gaetano G. Severe thrombocytopenia delays but does not prevent the occlusion of an arterial prosthesis in rats. Thromb Haemost 1981; 46: 558-60.
9. Shand RA, Smith JR, Wallis RB. Expression of the platelet procoagulant activity in vivo in thrombus formation in an extracorporeal shunt in the rat. Thromb Res 1984; 36: 223-32.
10. Lockyer S, Kambayashi J. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. J Cardiovasc Pharmacol 1999; 33: 718-25.
11. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-6.
12. Merhi Y, Lam JY, Lacoste LL, Latour JG, Guidoin R, Waters D. Effects of thrombocytopenia and shear rate on neutrophil and platelet deposition on endothelial and medial arterial surfaces. Arterioscler Thromb 1993; 13: 951-7.
13. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn, PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
14. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125-34.
15. Sato N, Mohri H, Fujimasa I, Imachi K, Atsumi K, Sezai Y, et al. Multivariate analysis of risk factors for thrombus formation in University of Tokyo ventricular assist device. J Thorac Cardiovasc Surg 1993; 106:520-7.
16. Jerushalmy Z, Payta M, Pinkhas J, De Vries A. Alteration of rat bone marrow megakaryocytes following administration of cytosine arabinoside, daunomycin and hydroxyurea. Haemostasis 1977; 6:110-7.
17. Long MW, Williams N, Ebbe S. Immature megakaryocytes in the mouse: physical characteristics, cell cycle status, and in vitro responsiveness to thrombopoietic stimulatory factor. Blood 1982; 59:569-75.
18. Tsimberidou AM, Giles FJ. Essential Thrombocythemia (ET). Moving from Palliation to Cure. Hematology 2002; 7:315-23.
19. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984; 52:325-8.
20. Seiler S, Arnold AJ, Grove RI, Fifer CA, Keely SL Jr, Stanton HC. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes. J Pharmacol Exp Ther 1987; 243: 767-74.
21. Venuti MC, Stephenson RA, Alvarez R, Bruno JJ, Strosberg AM. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo [2,1-b] quinazoline. J Med Chem 1988; 31: 2136-45.
22. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997; 23: 379-83.
23. James CW. Anagrelide-induced cardiomyopathy. Pharmacotherapy 2000; 20: 1224-7.
24. Lane WJ, Hattori K, Dias S, Peerschke EI, Moore MA, Blanset DL, et al. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp Hematol 2001; 29: 1417-24.
25. Erusalimsky JD, Hong Y, Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline (RL603)? Exp Hematol 2002; 30: 625-6.
26. Tsimberidou AM, Giles FJ. Essential Thrombocythemia (ET): Moving from Palliation to Cure. Hematology 2002 Dec; 7(6): 315-23;
27. Barbui T. What is the standard treatment in essential thrombocythemia. Int J Hematol 2002; 76(Suppl 2): 311-7.
28. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 1998; 24: 9-13.
29. Storen EC and Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia, Blood 2001; 97: 863-866.
30. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002; 99: 1602-9.
31. Sohngen D, Hattstein E, Heyll A, Kuntz BM, Meckenstock G, Schneider W. Ex-vivo bleeding time as a control for platelet transfusion. Beitr Infusionsther Transfusionsmed 1994; 32: 459-66.
32. Orlikowski CE, Rocke DA, Murray WB, Gouws E, Moodley J, Kenoyer DG, et al. Thrombelastography changes in pre-eclampsia and eclampsia. Br J Anaesth 1996; 77: 157-61.
33. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984; 37: 359-64.
34. Buchanan GR, Holtkamp CA. Prednisone therapy for children with newly diagnosed idiopathic thrombocytopenic purpura. A randomized clinical trial. Am J Pediatr Hematol Oncol 1984; 6: 355-61.
35. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-35.
36. Myers DD Jr, Henke PK, Wrobleski SK, Hawley AE, Farris DM, Chapman AM, et al. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J Vasc Surg 2002; 36: 928-38.
37. Sullivan VV, Hawley AE, Farris DM, Knipp BS, Varga AJ, Wrobleski SK, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res 2003; 109: 1-7.
38. Myers D Jr, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolman L, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res 2002; 108: 212-21.
39. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
40. Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86: 75-82.
41. Baird TR, Walsh PN. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation. J Biol Chem 2002; 277: 38462-7.
42. Bolton-Maggs PH. Factor XI deficiency and its management. Haemophilia 2000; 6(Suppl. 1): 100-109.
43. Gutensohn K, Beythien C, Bau J, Fenner T, Grewe P, Koester R, et al. In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 2000; 99: 577-85.
44. Himmelreich G, Ullmann H, Riess H, Rosch R, Loebe M, Schiessler A, et al. Pathophysiologic role of contact activation in bleeding followed by thromboembolic complications after implantation of a ventricular assist device. ASAIO J 1995; 41: M790-4.
45. al-Mondhiry HH, Pierce WS. Hemostatic abnormalities in two patients implanted with total artificial hearts. Artif Organs 1989; 13: 464-9.
46. Jones DW, MacKie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001; 113: 550-2.
47. Kitchens CS. The contact system. Arch Pathol Lab Med 2002; 126: 1382-6.
48. Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency - a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999; 82: 1240-6.
49. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-8.
50. Jansen PM, Pixley RA, Brouwer M, de Jong IW, Chang AC, Hack CE, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87: 2337-44.
51. Walsh PN. Roles of platelets and FXI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86: 75-82.
52. von dem Borne PA, Koppelman SJ, Bouma BN, Meijers JC. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72: 397-402.
53. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
54. von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
55. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
56. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
57. Berliner JI, Rybicki AC, Kaplan RC, Monrad ES, Freeman R, Billett HH. Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb Res 2002; 107: 55-60.
58. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeC13-induced injury of the carotid artery in the mouse [letter]. Thromb Haemost 2002; 87: 774-776.
59. Chan JC, Ganopolsky JG, Cornelissen I, Suckow MA, Sandoval-Cooper MJ, Brown EC, et al. The characterization of mice with a targeted combined deficiency of protein c and factor XI. Am J Pathol 2001; 158: 469-79.
60. Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003, in press
61. Seligsohn U, Peretz H. Molecular genetics aspects of factor XI deficiency and Glanzmann thrombasthenia. Haemostasis 1994; 24: 81-5.
62. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-8.
63. Linden JV, Kolakoski MH, Lima JE, Du P, Lipton RA. Factor concentrate usage in persons with hemophilia in New York State. Transfusion 2003; 43: 470-475.
64. Kitchens CS. Factor XI: a review of its biochemistry and deficiency. Semin Thromb Hemost 1991; 17: 55-72.
65. Dempfle CE, Pfitzner SA, Schott D, Niessen KH, Heene DL. Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW- and LMW'-fibrinogen. Thromb Haemost 1997; 77: 879-83.
66. Drew AF, Kaufman AH, Kombrinck KW, Danton MJ, Daugherty CC, Degen JL, et al. Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998; 91: 1616-24.
67. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
68. Schott D, Dempfle CE, Beck P, Liermann A, Mohr-Pennert A, Goldner M, et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998; 339: 1679-86.
69. Mingers AM, Heimburger N, Zeitler P, Kreth HW, Schuster V. Homozygous type I plasminogen deficiency. Semin Thromb Hemost 1997; 23: 259-69.
70. Schuster V, Mingers AM, Seidenspinner S, Nussgens Z, Pukrop T, Kreth HW. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood 1997; 90: 958-66.
71. Mahan EF 3rd, Chandler JW, Rogers WJ, Nath HR, Smith LR, Whitlow PL, et al. Heparin and infarct coronary artery patency after streptokinase in acute myocardial infarction. Am J Cardiol 1990; 65: 967-72.
72. Ganger KH, Nachbur BH, Ris HB, Zurbrugg H. Surgical thrombectomy versus conservative treatment for deep venous thrombosis; functional comparison of long-term results. Eur J Vasc Surg 1989; 3: 529-38.
73. Saarinen J, Kallio T, Lehto M, Hiltunen S, Sisto The occurrence of the post-thrombotic changes after an acute deep venous thrombosis. A prospective two-year follow-up study. J Cardiovasc Surg (Torino) 2000; 41: 441-6.
74. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest 1994; 106: 718-24.
75. Taylor FB Jr, Hoogendoorn H, Chang AC, Peer G, Nesheim ME, Catlett R, et al. Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C. Blood 1992; 79: 1720-8.
76. Callas PW, Tracy RP, Bovill EG, Cannon C, Thompson B, Mann KG. The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial. J Thromb Thrombolysis 1998; 5: 53-60.
77. Weitz JI, Leslie B, Hirsh J, Klement P. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest 1993; 91: 1343-50.
78. Weitz JI. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol 1995; 6: 19S-23S.
79. Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-53.
80. Sakharov DV, Lijnen HR, Rijken DC. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271: 27912-8.
81. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
82. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene, Blood 1997; 90: 204-8.
83. Abrahamsson T, Nerme V, Stromqvist M, Akerblom B, Legnehed A, Pettersson K, et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-26.
84. Paganelli F, Alessi MC, Morange P, Maixent JM, Levy S, Vague IJ. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost 1999; 82: 104-8.
85. Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
86. Schatteman K, Goossens F, Leurs J, Verkerk R, Scharpe S, Michiels JJ, et al. Carboxypeptidase U at the interface between coagulation and fibrinolysis. Clin Appl Thromb Hemost 2001; 7: 93-101.
87. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5: 372-5.
88. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
89. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
90. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
91. Mattsson C, Bjorkman JA, Abrahamsson T, Nerme V, Schatteman K, Leurs J, et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87: 557-62.
92. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
93. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
94. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
95. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-6.
96. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-12.
97. Strukova SM, Kogan AE, Tara AA, Aaviksaar AA. Antithrombotic effect of protein C activator from a snake venom. Vopr Med Khim 1989; 35: 115-9.
98. Kogan AE, Bashkov GV, Bobruskin ID, Romanova EP, Makarov VA, Strukova SM. Protein C activator from the venom of Agkistrodon blomhoffi ussuriensis retards thrombus formation in the arterio-venous shunt in rats. Thromb Res 1993; 70: 385-93.
99. Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem 2002; 277: 27581-4.
100. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002; 61: 490-501.
101. Ono M, Nawa K, Marumoto Y. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis. Thromb Haemost. 1994; 72: 421-5.
102. Aoki Y, Takei R, Mohri M, Gonda Y, Gomi K, Sugihara T, et al. Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats. Am J Hematol 1994; 47: 162-6.
103. Mohri M, Gonda Y, Oka M, Aoki Y, Gomi K, Kiyota T, et al. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 1997; 8: 274-83.
104. Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ, et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003, in press.
105. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-42.
106. Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-94.
107. Fernandez JA, Kojima K, Petaja J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells Mol Dis 2000; 26: 115-23.
108. Deguchi H, Fernandez JA, Hackeng TM, Banka CL, Griffin JH. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci U S A 2000; 97: 1743-8.
109. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-27.
110. Lentz SR, Miller FJ Jr, Piegors DJ, Erger RA, Fernandez JA, Griffin JH, et al. Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. Circulation 2002; 106: 842-6.
111. Lentz SR, Fernandez JA, Griffin JH, Piegors DJ, Erger RA, Malinow MR, et al. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. Arterioscler Thromb Vasc Biol 1999; 19: 1744-50.
112. Deguchi H, Fernandez JA, Griffin JH. Neutral glycosphingolipid-dependent inactivation of coagulation factor Va by activated protein C and protein S. J Biol Chem 2002; 277: 8861-5.
113. Deguchi H, Fernandez JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001; 97: 1907-14.
114. Yegneswaran S, Deguchi H, Griffin JH. Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human and bovine activated protein C with negatively charged phospholipid vesicles. J Biol Chem 2003, in press.
115. Griffin JH, Deguchi H, Fernandez JA. Causes of thrombophilia yet to be discovered: a personal view. Haemostasis 2000; 30: 26S-33S.
116. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962-7.
117. Blum JE, Handmaker H. Small peptide radio pharmaceuticals in the imaging of acute thrombus. Curr Pharm Design 2002; 8(20): 1815-26.
118. Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Design 2002; 8(3): 201-13.
119. Rockway TW, Nienaber V, Giranda VL. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Design 2002; 8(28): 2541-58.